Janus Kinase Inhibitor

In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discusses the role of JAK inhibitors in rheumatoid arthritis treatment, and growing understanding of their effects.

Based on the pathogenesis of eosinophilic cellulitis, treatment targeting Janus kinase 1 and 2 should be developed to treat this disease, according to a study.

The FDA has approved Litfulo, a once-daily oral treatment, for the treatment of severe alopecia in individuals aged 12 years and older, Pfizer announced in a press release.

The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.

NEW ORLEANS — In this Healio video exclusive, Ronda S. Farah, MD, discusses how reducing Janus kinase inhibitor dosages in patients with alopecia areata should be completed safely.

Clinical data found “no evidence” of a higher short-term cancer risk, except for non-melanoma skin cancer, in patients with rheumatoid arthritis or psoriatic arthritis starting Janus kinase inhibitors vs. TNF inhibitors, researchers wrote.

NEW ORLEANS — In this Healio exclusive video, Brett King, MD, PhD, discusses highlights from the American Academy of Dermatology Annual Meeting, including results from the second phase 3 trial of deuruxolitinib.

NEW ORLEANS — A first-in-human study found patients with lichen planus treated with the Janus kinase inhibitor baracitinib achieved almost total improvement, according to a presenter at the American Academy of Dermatology Annual Meeting.